Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury

Circulation. 2009 Oct 20;120(16):1606-15. doi: 10.1161/CIRCULATIONAHA.109.872200. Epub 2009 Oct 5.

Abstract

Background: Transforming growth factor-beta family cytokines have diverse actions in the maintenance of cardiac homeostasis. Activin A is a member of this family whose regulation and function in heart are not well understood at a molecular level. Follistatin-like 3 (Fstl3) is an extracellular regulator of activin A protein, and its function in the heart is also unknown.

Methods and results: We analyzed the expression of various transforming growth factor-beta superfamily cytokines and their binding partners in mouse heart. Activin betaA and Fstl3 were upregulated in models of myocardial injury. Overexpression of activin A with an adenoviral vector (Ad-actbetaA) or treatment with recombinant activin A protein protected cultured myocytes from hypoxia/reoxygenation-induced apoptosis. Systemic overexpression of activin A in mice by intravenous injection of Ad-actbetaA protected hearts from ischemia/reperfusion injury. Activin A induced the expression of Bcl-2, and ablation of Bcl-2 by small interfering RNA abrogated its protective action in myocytes. The protective effect of activin A on cultured myocytes was abolished by treatment with Fstl3 or by a pharmacological activin receptor-like kinase inhibitor. Cardiac-specific Fstl3 knockout mice showed significantly smaller infarcts after ischemia/reperfusion injury that was accompanied by reduced apoptosis.

Conclusions: Activin A and Fstl3 are induced in heart by myocardial stress. Activin A protects myocytes from death, and this activity is antagonized by Fstl3. Thus, the relative expression levels of these factors after injury is a determinant of cell survival in the heart.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activin Receptors / pharmacology
  • Activins / administration & dosage
  • Activins / antagonists & inhibitors
  • Activins / genetics
  • Activins / metabolism*
  • Animals
  • Animals, Newborn
  • Apoptosis / drug effects
  • Cell Hypoxia
  • Cell Survival
  • Cells, Cultured
  • Coronary Vessels
  • Disease Susceptibility
  • Follistatin-Related Proteins / genetics
  • Follistatin-Related Proteins / metabolism*
  • Follistatin-Related Proteins / pharmacology
  • Gene Transfer Techniques
  • Heart Ventricles
  • Injections, Intravenous
  • Ligation
  • Male
  • Mice
  • Mice, Knockout
  • Myocardial Infarction / metabolism
  • Myocardial Ischemia / etiology*
  • Myocardial Reperfusion Injury / prevention & control
  • Myocardium / metabolism*
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Oxygen / pharmacology
  • Rats
  • Recombinant Proteins / administration & dosage
  • Up-Regulation

Substances

  • Follistatin-Related Proteins
  • Recombinant Proteins
  • activin A
  • Activins
  • Activin Receptors
  • Oxygen